{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-318435","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.869803+00:00","generated_at":"2026-06-28T14:35:58.741145+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO","bullets":["Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.","Net loss of $6.6M ($0.72/sh) for Q3 2021 vs $2.3M ($1.47/sh) in Q3 2020.","Nominated TYRA-200 (FGFR2 inhibitor) for clinical development; IND expected 2H 2022.","Appointed Esther van den Boom CFO, John Healy GC, Allison Kemner VP, Rehan Verjee to board.","R&D expenses $5.5M (up from $1.9M) driven by pipeline advancement and personnel costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-318435","json":"https://secwatch.observer/filing/0001193125-21-318435.json","markdown":"https://secwatch.observer/filing/0001193125-21-318435.md","text":"https://secwatch.observer/filing/0001193125-21-318435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/0001193125-21-318435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312521318435/d223896d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:35:58.741145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}